Alan Shackelford
Founder
Shackelford Pharma
Shackelford Pharma leverages over 27,000 real patient interactions to identify and develop therapeutic candidates, focusing on epilepsy. Its lead drug candidate, SP1707, is built on decades of treatment data and is being advanced through FDA regulatory pathways to address unmet needs in epilepsy care.
- Biotechnology
Updated 4 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Patients with epilepsy often have limited treatment options, leading to refractory seizures and poor quality of life. Existing therapies may be ineffective or poorly tolerated, and development of new drugs is slow due to limited real‑world efficacy data.
Solution
Shackelford Pharma leverages a proprietary database of over 27,000 patient interactions collected by Dr. Alan Shackelford to identify promising therapeutic candidates for epilepsy. By analyzing real‑world efficacy and safety outcomes, the company selects and advances compounds with demonstrated potential, accelerating the development timeline. Its lead candidate, SP1707, is built on decades of treatment data and preclinical studies, and is being progressed through FDA regulatory pathways to address unmet medical needs in epilepsy care. The approach combines extensive clinical experience with data‑driven candidate selection to increase the likelihood of clinical success.
Target Audience
Primary customers are pharmaceutical partners, clinical researchers, and healthcare providers seeking new, evidence‑backed therapies for patients with refractory or unmet‑need epilepsy.
Features
- Proprietary real‑world evidence database comprising >27,000 patient outcomes from cannabinoid‑based and other treatments
- Data‑driven candidate identification that prioritizes compounds with documented efficacy and safety in refractory epilepsy
- Lead drug candidate SP1707 supported by hundreds of patient‑treatment years and preclinical animal data
- Experienced R&D team with 320+ years of collective drug development experience, including leadership on 43 FDA‑approved drugs
- Focused regulatory strategy to advance SP1707 through FDA pathways for epilepsy indications